BioNTech SE (BNTX) Stock: Why It’s Headed Down


BioNTech SE (BNTX) is falling in the market today. The stock, one that is focused in the biotechnology industry, is presently priced at $12.91 after tumbling -6.58% so far in today’s session. As it relates to biotechnology stocks, there are quite a few aspects that have the ability to lead to price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines relating to BNTX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-10-19 03:19PM UPDATE 1-European biotech firm BioNTech reverses course in early trading
11:21AM European biotech firm BioNtech jumps 10% in U.S. market debut
07:31AM The Daily Biotech Pulse: UCB To Buy Ra Pharma, Reata Reacquires Rights To Nrf2 Activators From AbbVie, BioNTech IPO
03:16AM BioNTech Announces Pricing of Initial Public Offering
Oct-07-19 07:53AM IPO Outlook For The Week: Banking And Biotech

However, when making a decision to invest, investors should look into much more than news, especially in the generally speculative biotechnology sector. Here’s what’s going on with BioNTech SE.

Returns That BNTX Investors Have Seen

While a decline in a single session, like the move that we’re seeing from BioNTech SE might lead to fear in some investors, a single session decline alone should not be the basis of a decision to, or not to, invest in a stock. It’s always smart to look into trends for a period longer than a single trading session. In the case of BNTX, below are the movements that investors have seen:

  • Past 7 Days – Throughout the last seven days, BNTX has generated a change in price in the amount of 0.
  • Past 30 Days – The ROI from BioNTech SE over the last 30 days works out to 0.
  • Past Three Months – Throughout the past 3 months, the company has generated a ROI that comes to 0
  • Past 6 Months – Throughout the last 6 months, investors have seen a change that amounts to 0 from the stock.
  • Year To Date – Since the the last trading session of last year BNTX has resulted in a return of -2.95%.
  • Annually – Lastly, in the last full year, we’ve seen performance that comes to 0 out of BNTX. Throughout this period of time, the stock has traded at a high price of -22.69% and a low price of -0.77%.

Ratios That Are Notable

Looking at a few key ratios associated with a stock generally gives prospective investors a look of how dangerous and/or potentially profitable a an investment option might be. Below are some of the key ratios to consider when looking at BNTX.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the level of short interest. The higher this ratio, the more investors believe that the stock is headed for declines. Throughout the sector, biotechnology stocks tend to carry a higher short ratio. However, we tend to see quite a few short squeezes in the industry. Nonetheless, when it comes to BioNTech SE, it’s short ratio amounts to 0.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure the company’s abilities to pay for its debts when they mature with only current assets or quick assets. In the biotechnology space, companies are reliant on continued support from investors, the current and quick ratios can look bad. However, some gems in the biotechnology sector do have good quick and current ratios. As it relates to BNTX, the quick and current ratios total up to 3.70 and 3.70 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. as it relates to BioNTech SE, the book to share value ratio works out to 0.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of the company’s stock. Many early stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a biotechnology stock, this is an important ratio to think about. In this case, the cash to share value ratio is 2.24.

What Analysts Think About BioNTech SE

Although it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions in order to validate your own due diligence before making an investment decision in the biotechnology industry. Below are the most recent moves that we’ve seen from analysts when it comes to BNTX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Is Big Money Interested in BioNTech SE?

An interesting fact that I have learned so far in my short time on Earth has been that good investors tend to follow the moves made by big money. In general, investors that are looking to keep their investments relatively safe will keep their eyes on trades made by institutional investors and insiders of the company. With that said, is big money interested as it relates to BNTX? Here’s the scoop:

Institutions own 0 of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 0 percent of BNTX shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Traders seem to be interested in the total numbers of shares both available and outstanding. As it relates to BioNTech SE, there are currently 233.14M and there is a float of 214.95M. This means that out of the total of 233.14M shares of BNTX that are out there today, 214.95M are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to BNTX, the short percent of the float is 0.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, BNTX has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 0 and revenue has seen movement of 19.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can look through social media trends and other publicly available information, but, like humans, I learn much faster when I have the help of a teacher. If you would to help me learn something, I’d love to learn! Is there other information that captures your interest? Should I say something differently? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here